Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic TherapyPreclinical Optimization of Anti-BCMA/CD3 Therapy in Myeloma

Overview of attention for article published in Blood Cancer Discovery, May 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#32 of 214)
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 5 news outlets

twitter: 47 X users

Citations

dimensions_citation: 42 Dimensions

Readers on

mendeley: 37 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 5 news stories from 5 outlets.

Mayo Clinic Researchers Study New Class of Drugs to Treat Multiple Myeloma

FirstWord Pharma, 15 Jun 2021

Newswise — PHOENIX — Mayo Clinic researchers are studying a new class of immunotherapy drugs called "bispecific antibodies…

Mayo Clinic Researchers Study New Class of Drugs to Treat Multiple Myeloma

Newswise, 14 Jun 2021

Newswise — PHOENIX — Mayo Clinic researchers are studying a new class of immunotherapy drugs called "bispecific antibodies…

Model Clarifies Immunotherapy for Multiple MyelomaDiscovery's Edge

Mayo Discoverys Edge, 14 Jun 2021

Using a mouse model of the blood cancer multiple myeloma, scientists at Mayo Clinic in Arizona are once again providing insight…

Researchers study new class of drugs to treat multiple myeloma

Mirage News, 14 Jun 2021

PHOENIX – Mayo Clinic researchers are studying a new class of immunotherapy drugs called “bispecific antibodies” that have…

Mayo Clinic researchers study new class of drugs to treat multiple myeloma

Sciencenewsnet.in, 14 Jun 2021

Post Views: 4 PHOENIX Mayo Clinic researchers are studying a new class of immunotherapy drugs called “bispecific antibodies…